Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug

Sandoz Group AG (OTC:SDZNY) (OTC:SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ:AMGN) for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel (etanercept), first approved by the U.S. Food and Drug Administration (FDA) in 1998.

Etanercept is a biologic medicine used to treat various inflammatory diseases.

Sandoz alleges that Amgen blocked competition from more cost-effective biosimilar competitors, including Sandoz etanercept biosimilar, Erelzi+ (etanercept-szzs), by unlawfully purchasing and using certain patent rights to entrench its position in the market.

Also Read: FDA Approves Amgen’s Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder

In 2024, Enbrel generated $3.3 billion in revenue in the U.S.

Sandoz received FDA approval for Erelzi in 2016, the same year the company launched the medicine in Europe.

Sandoz is seeking an injunction to prevent Amgen from using certain patent rights to block biosimilar competition and allow Sandoz to ...

https://www.benzinga.com/general/biotech/25/04/44795469/sandoz-files-lawsuit-alleging-amgen-illegally-blocked-biosimilar-competition-for-its-blockbuster-